Table 2 Therapeutic, clinical and immunovirologic characteristic of the study participants at ART initiation (n = 113)

No of patients initiated ART

28

85

Demographic

  Female, n (%)

14 (50)

56 (65.7)

  Age, years

34.1 ± 8.3

34.4 ± 7.7

Treatment

Mean follow-up days before ART initiation

78.7

37.7

Mean delay in commencing HAART following TB treatment, days

100

HAART regimen at ART initiation, n (%)

  D4T/3TC/NVP

4 (15)

66 (78)

  D4T/3TC/EVZ

11(41)

2 (2)

  AZT/3TC/NVP

7(26)

12 (14)

  AZT/3TC/EVZ

5 (16)

4 (5)

  Others

1 (1)

Cortimoxzole treatment, n (%)

15 (83.3%)

58 (59.2%)

BMI and Laboratory values at ART initiation

  BMI (kg/m²)

18.1 ± 2.5

21.3 ± 3.7

0.0001

  CD4+ (cells/μl)

110.3 ± 71.3

197.8 ± 153.2

0.005

  CD4%

10.1 ± 5.3

14.6 ± 9.9

0.033

  TLC (cells/μl)

1078 ± 512

1521 ± 692

0.007

  Hgb (g/dl)

13.4 ± 3.4

13.0 ± 2.5

0.68

  HIV RNA (log₁₀copies/ml)

4.3 ± 0.9

4.3 ± 0.9

0.73

Follow-up outcomes

Deaths, n (%)

8/59 (13.6)

10/125 (8.0%)